東陽光藥(01558.HK)向宜昌東陽光生物科技出資2700萬元持股90%
格隆匯12月12日丨東陽光藥(01558.HK)公佈,於2019年12月12日,公司與宜都東陽光實業就宜昌東陽光生物科技訂立出資協議。宜昌東陽光生物科技的註冊資本總額為人民幣3,000萬元。根據出資協議,公司同意以現金出資人民幣2,700萬元,佔宜昌東陽光生物科技註冊資本總額的90%。由於公司佔有宜昌東陽光生物科技90%的股份權益,因此其成為公司附屬公司。
宜昌東陽光生物科技經營範圍為研發、生產、銷售醫藥中間體、精細化學品及相關技術開發、諮詢、推廣服務;貨物及技術進出口業務。該公司計劃透過宜昌東陽光生物科技推進宜都基地醫藥中間體項目。
公司認為,與宜都東陽光實業訂立出資協議並設立宜昌東陽光生物科技,自主生產供應醫藥中間體,將有利於提高供應鏈安全、藥品質量安全以及原料藥和製劑綜合競爭能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.